GONADOTROPIN-RELEASING HORMONE PREVENTS OVARIAN FAILURE IN PREMENOPAUSAL WOMEN WITH BREAST CANCER, SHOWS STUDY
Researchers from Italy have reported that the administration of the gonadotropin releasing hormone analogue goserelin (Gn-RH) prevents ovarian failure in women with early breast cancer receiving chemotherapy. The details of this report appeared in the journal Cancer.
Researchers previously reported the outcomes of 64 premenopausal women with early breast cancer treated with goserelin for one year. Approximately half the patients in this study were hormone receptor positive and half were negative. They reported that serum estradiol was significantly suppressed to low levels. The average age of this group of women was 42 years, and 86 percent resumed menstruation after completion of adjuvant chemotherapy. Hormone positive patients received tamoxifen. They also reported that 84 percent of these patients were alive and disease-free.
The current study included 64 women with stage II breast cancer and 36 with stage III breast cancer who had an average age of 43 years. A total of 26 patients received CMF, 74 received anthracycline based regimens and nine patients received an autologous stem cell transplant. Taxanes were given to those positive for HER-2. The median follow-up of this study was 75 months.